Barclays cuts Aspen Aerogels stock rating, slashes target to $7

Barclays downgraded Aspen Aerogels (ASPN) from "Overweight" to "Equal Weight," slashing the price target to $7 from $13, citing diminishing EV tax credits and General Motors' slowed EV production, which will reduce Aspen's 2025 revenue forecast by 20%. This revision follows a 78% stock decline over the past year and Q1 2025 earnings miss, with Oppenheimer also downgrading the stock from Outperform to Perform. ASPN is undertaking restructuring efforts and exploring cost recovery options for its Georgia facility.

Analysis

Barclays has downgraded Aspen Aerogels (ASPN) to "Equal Weight" from "Overweight," concurrently slashing the price target to $7.00 from $13.00, primarily due to diminishing EV tax credits and General Motors' (GM) decision to decelerate its domestic electric vehicle production. This revised outlook has led Barclays to cut Aspen's estimated 2026 EBITDA by 20%, its 2025 revenue forecast by 20%, and its 2025 adjusted EBITDA by a substantial 50%. The downgrade reflects a significant reduction in GM's projected vehicle production, with Barclays' Auto analyst forecasting approximately 160,000 units in 2025 and under 120,000 in 2026, a stark contrast to the initial expectation of 235,000 for 2025. This news compounds existing pressures on Aspen, whose stock has plummeted 78% over the past year, although InvestingPro's Fair Value analysis suggests it may be undervalued against a current analyst target range of $8 to $32.

Aspen Aerogels is grappling with a confluence of challenges including a slowdown in the US EV market, tariff impacts, and a withdrawn Department of Energy loan for capacity expansion, necessitating a revised manufacturing strategy and cost reductions. Despite these headwinds and a reported negative EBITDA of $210.6 million in the last twelve months, the company achieved 51.9% revenue growth over the same period and maintains a healthy current ratio of 4.22 with moderate debt. However, recent Q1 2025 results missed expectations, with EPS at -$0.06 (versus -$0.05 forecast) and revenue at $78.7 million (versus $82.74 million forecast), marking a 17% year-over-year revenue decline. Consequently, Oppenheimer also downgraded ASPN stock from Outperform to Perform, citing the earnings miss, lackluster guidance, and slower-than-anticipated EV market transition.

In response, Aspen is undertaking restructuring, exploring $30-50 million in cost recovery for its Georgia facility, and renegotiating debt covenants with MidCap Financial. The production ramp-up for EV programs is now anticipated next year, delaying revenue streams. Despite these setbacks, Aspen has secured major awards with GM, Mercedes Benz, and Volvo Trucks, and is focusing on cost reduction and expansion into prismatic cell battery products. For Q2 2025, Aspen projects revenue between $70 and $80 million and adjusted EBITDA from breakeven to $7 million, indicating a cautious operational stance amidst these significant market and company-specific difficulties, underscored by a strongly negative overall sentiment score of -0.75.

Key Decisions for Investors

• Investors should exercise significant caution given the multiple analyst downgrades, recent earnings miss, reduced corporate guidance, and substantial headwinds from key customer GM's production cuts and the broader EV market slowdown.
• Monitor Aspen Aerogels' progress on its announced restructuring efforts, cost recovery initiatives for the Georgia facility, and the renegotiation of its debt covenants, as these are critical for near-term financial stability and operational viability.
• While the stock appears undervalued by some metrics and holds long-term contracts with major OEMs, the current operational uncertainties, negative EBITDA, and market headwinds warrant a careful risk assessment before considering new or increased positions; existing shareholders may consider holding pending clearer signs of a turnaround.
• Closely track developments in the US EV market, particularly regarding tax credits and demand trends, as well as Aspen's ability to secure alternative funding or successfully pivot its manufacturing strategy to mitigate current challenges and capitalize on its niche thermal barrier products.